Stroke Research

Stroke is classified as both a neurological and a cardiovascular disease, as it is a disruption in blood supply to the brain which causes the neurological abnormalities. There are two types of stroke; ischemic and hemorrhagic.

Stroke Research Products Targets

Products for Stroke Research - Page 6

Cat.No. Product Name Information/Activity
BCC6556 Dihydrokainic acid 52497-36-6
BCC6815 Evans Blue tetrasodium salt Selective P2X purinergic antagonist,Evans Blue is a potent inhibitor of L-glutamate uptake via the membrane bound excitatory amino acid transporter (EAAT).
BCC7295 (±)-HIP-B 227619-65-0
BCC6565 L-(-)-threo-3-Hydroxyaspartic acid 7298-99-9
BCC6804 (±)-threo-3-Methylglutamic acid 63088-04-0
BCC6873 MPDC MPDC is a potent and competitive inhibitor of the Na+-dependent high-affinity glutamate transporter in forebrain synaptosomes.
BCC6595 L-trans-2,4-PDC 64769-66-0
BCC6840 SYM 2081 SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively.
BCC5735 DL-TBOA DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC50s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [14C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with Ki valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with Ki values of 4.4 μM and 3.2 μM, respectively.
BCC5919 TFB-TBOA 480439-73-4